newdrugapprovals.org
Phase 2 , Sarepta, shows eteplirsen for Duchenne muscular dystrophy
ETEPLIRSEN 27 MAR 2013 The clock is ticking for Sarepta Therapeutics , a multitude of biotech investors and the boys who suffer from Duchenne muscular dystrophy. Armed with promising Phase IIb data…